Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Darya-Varia Laboratoria TbkISX:DVLA +0.63%74 Return-on-Tangible-Asset is 6.14% as of Jun. 2026, which is 24% below its 10-year median of 8.11. GuruFocus rates ISX:DVLA with a GF Score™ of 74/100 and a GF Value™ of Rp1,861.38 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, PT Darya-Varia Laboratoria Tbk ranks better than 62.56% on this metric.
The historical rank and industry rank for PT Darya-Varia Laboratoria Tbk's Return-on-Tangible-Asset or its related term are showing as below:
ISX:DVLA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.7 Med: 8.11 Max: 12.74
Current: 5.7
During the past 13 years, PT Darya-Varia Laboratoria Tbk's highest Return-on-Tangible-Asset was 12.74%. The lowest was 5.70%. And the median was 8.11%.
ISX:DVLA's Return-on-Tangible-Asset is ranked better than 62.56% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.98
vs ISX:DVLA: 5.70
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
PT Darya-Varia Laboratoria Tbk Return-on-Tangible-Asset Related Terms
PT Darya-Varia Laboratoria Tbk Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:DVLA vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Darya-Varia Laboratoria Tbk's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Darya-Varia Laboratoria Tbk Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Darya-Varia Laboratoria Tbk's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where PT Darya-Varia Laboratoria Tbk's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 6.14% mean?
PT Darya-Varia Laboratoria Tbk (ISX:DVLA) has a Return-on-Tangible-Asset of 6.14% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. This is 24% below median its historical median of 8.11. Over the past decade, PT Darya-Varia Laboratoria Tbk's Return-on-Tangible-Asset has ranged from 5.70 to 12.74. According to the industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #377 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 37.4%.
Is PT Darya-Varia Laboratoria Tbk's Return-on-Tangible-Asset too high?
PT Darya-Varia Laboratoria Tbk's current Return-on-Tangible-Asset of 6.14% is 24% below median its 10-year median of 8.11. Over the past 10 years, this metric has ranged from a low of 5.70 to a high of 12.74. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.98. PT Darya-Varia Laboratoria Tbk's value of 6.14% is 106% above this industry median. Based on the distribution chart, PT Darya-Varia Laboratoria Tbk ranks #377 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PT Darya-Varia Laboratoria Tbk has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Darya-Varia Laboratoria Tbk's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #377 out of 1007 companies for Return-on-Tangible-Asset. This puts PT Darya-Varia Laboratoria Tbk in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.98. PT Darya-Varia Laboratoria Tbk's value of 6.14% is 106% above this benchmark. Historically, PT Darya-Varia Laboratoria Tbk's own Return-on-Tangible-Asset has ranged from 5.70 to 12.74 over the past decade. While the company's 10-year median is 8.11 vs. the industry median of 2.98, PT Darya-Varia Laboratoria Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.98, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Darya-Varia Laboratoria Tbk's current Return-on-Tangible-Asset of 6.14% is 106% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Darya-Varia Laboratoria Tbk's current Return-on-Tangible-Asset is 6.14%, which is 24% below median its own 10-year median of 8.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Darya-Varia Laboratoria Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk (ISX:DVLA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp1,861.38, compared to a current price of Rp1,585.00 — trading 14.8% below its estimated fair value. The current Return-on-Tangible-Asset is 6.14%, which is 24% below median its 10-year median of 8.11 and 106% above the Drug Manufacturers industry median of 2.98. PT Darya-Varia Laboratoria Tbk's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For PT Darya-Varia Laboratoria Tbk (ISX:DVLA), the current Return-on-Tangible-Asset is 6.14% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk stock appears to be undervalued.
The current stock price of Rp1,585.00 is trading 14.8% below its estimated GF Value™ of Rp1,861.38.
GuruFocus considers PT Darya-Varia Laboratoria Tbk to be Modestly Undervalued.
Key valuation signals for ISX:DVLA:
Return-on-Tangible-Asset: 6.14% (24% below median its 10-year median of 8.11)
GF Value™: Rp1,861.38 vs. price of Rp1,585.00 (14.8% below fair value)
Industry Position: 106% above the Drug Manufacturers median (#377 of 1007)
No single metric tells the full story. See the ISX:DVLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, and equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics, wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory testing services, periodic inspection services, and many more activities. Its business segments include: prescription drugs; consumer health products, which derives key revenue; export and toll manufacturing services; and services.
74GF Score
Get the complete analysis for ISX:DVLA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DVLA has been successfully added to your 
